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impairments. To address these issues, national and regional neonatal networks around the world collect 
and analyse data from their constituents to identify trends in outcomes, and conduct benchmarking, audit 
and research. Improving neonatal outcomes and reducing health care costs is a global problem that can be 
addressed using collaborative approaches to assess practice variation between countries, conduct research 
and implement evidence-based practices. The International Network for Evaluating Outcomes (iNeo) of 
neonates was established in 2013 with the goal of improving outcomes for very preterm neonates through 
international collaboration and comparisons. To date, 10 national or regional population-based neonatal 
networks/datasets participate in iNeo collaboration. The initiative now includes data on >200,000 very 
preterm neonates and has conducted important epidemiological studies evaluating outcomes, variations 
and trends. The collaboration has also surveyed >320 neonatal units worldwide to learn about variations in 
practices, healthcare service delivery, and physical, environmental and manpower related factors and support 
services for parents. The iNeo collaboration serves as a strong international platform for Neonatal-Perinatal 
health services research that facilitates international data sharing, capacity building, and global efforts to 
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ǂ, a full list of the International Network for Evaluating Outcomes (iNeo) of Neonates investigators is provided in the Appendix 1.
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Introduction 
The International Network for Evaluating Outcomes (iNeo) 
in neonates is an international collaboration of nearly 
population-based national neonatal networks/datasets 
including 10 networks from 11 countries: Australia, New 
Zealand, Canada, Finland, Israel, Japan, Spain, Sweden, 
Switzerland, Tuscany region of Italy and the UK. The 
network has been, and continues to be, a powerful platform 
for applied health services and policy research that is aiming 
to improve patient-oriented outcomes for very preterm 
(VPT, born before 32 weeks of gestational age) neonates 
both in the member countries and globally. Only 1% of all 
births and 14–20% of all preterm births are VPT neonates; 
however, the rate of VPT birth is important to public health 
because of these neonates are at high-risk for mortality and 
childhood morbidities including cerebral palsy, cognitive 
delay, blindness and deafness (1,2). In addition, the cost 
of caring for VPT neonates is high both during initial 
hospitalization (3) and the lifetime cost of permanent 
impairments. 
Various national and international networks/datasets, 
such as the Vermont Oxford Network in the USA (4), 
Canadian Neonatal Network (CNN) (5,6), Neonatal 
Data Analyses Unit in the UK (7) and Swedish Neonatal 
Quality Register (SNQ) (8,9) analyse data from their 
local populations to identify trends in outcomes of VPT 
neonates and benchmark the performance of centres 
within each network (2,3,10-15). Although most networks 
initially reported improvements in the rates of morbidity 
and mortality, recently CNN and other networks observed 
stagnant progress or worsening of outcomes (16-19). Even 
when continued outcome improvement was reported, 
there remained significant variation in the performance of 
units within neonatal networks. For example, Draper et al. 
reported the VPT survival rate varied from 74.8% to 93.2% 
between units in 10 European regions (20). In addition, 
the risk-adjusted mortality rate for VPT neonates in an 
Australia NICU was revealed to be lower than a Scottish 
NICU (21). However, generalizing results from a few 
NICUs to the population level risks introducing selection 
bias that can lead to inaccurate conclusions. 
Ten years ago, based on individual reports of outcomes, 
collaborations between the CNN, the Neonatal Research 
Network of Japan (NRNJ), the Australian and New 
Zealand Neonatal Network (ANZNN) and the Swedish 
Neonatal Quality (SNQ) register (9) were initiated. In 
the first population-based retrospective comparison, we 
identified that the composite outcome of mortality or any 
major morbidity [nosocomial infection (NI), necrotizing 
enterocolitis (NEC), severe neurological injury, retinopathy 
of prematurity (ROP), and bronchopulmonary dysplasia 
(BPD)] was lower in NRNJ than Canada in very low birth 
weight (VLBW) neonates. In-depth analyses revealed 
that the CNN had higher rates of NI, NEC, and severe 
neurological injury whereas NRNJ had higher rates of 
ROP and BPD (22). While the VPT neonate mortality rate 
was similar between Canada and Australia/New Zealand, 
rates of NEC, severe neurological injuries, ROP and BPD 
were significantly lower in Australia/New Zealand than 
Canada, while the rates of early-onset sepsis and air leaks 
were higher and the average length of stay was longer than 
Canada (23,24). 
While the variability in neonatal outcomes between 
Canada and other countries was clear, the factors contributing 
to the outcome variability were uncertain. Distinct population 
characteristics, differences in neonate severity of illness, 
diverse processes of care or delivery of health care could all 
contribute to outcome variability. For example, Australia/
New Zealand has a significantly lower number of outborn 
VPT neonates than Canada (23); respiratory therapists play a 
prominent role in North American institutions, but are rarely 
present in European countries; and in Canada junior doctors 
are less likely to do shift work than in Europe and Australia.
Given the myriad of factors that could contribute to 
outcome variability in between countries, it was important 
to first characterize these factors then identify specific 
methods to improve neonatal care in each country. The 
initial care of VPT neonates is highly complex and is 
typically delivered in specialized units (60–80% of VPT 
neonates are initially admitted to tertiary NICUs). When 
VPT neonates no longer need complex care, they are 
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transferred to Level 2 units for the remainder of their 
hospitalization. Both the day-to-day cost of caring for 
each neonate in the NICU and the cumulative lifetime 
cost of care consume an enormous amount of resources. 
Collaborative sharing and learning between countries to 
assess practice variations, provide evidence for evidence-
based practices, and monitor practice implementation had 
the potential to help improve outcomes and reduce health 
care costs globally. However, enabling rigorous comparisons 
between countries/networks required an understanding of 
the context for comparison in each country and a way to 
standardize data. 
These concepts, along with enthusiasm of participating 
networks/data custodians, led to the establishment of an 
iNeo collaboration in 2013 with funding support from the 
Institute of Human Development, Child and Youth Health 
at the Canadian Institutes of Health Research (25). The 
underlying premise of iNeo was to collect information 
from population-based networks/datasets on the outcomes, 
characteristics, practices and culture of the member sites; 
evaluate the impact of such variations on outcomes and 
to identify the best models of health service delivery 
(incorporating medical and non-medical variations); report 
back to the units the results of analyses; empower units to 
embrace implementation of data-linked and evidence-based 
practice changes and ultimately improve outcomes for VPT 
neonates both within the iNeo countries and globally. In 
the sections below, we highlight the aims of iNeo and their 
fulfilment to date and identify opportunities to both expand 
this initiative to other countries and improve trajectories of 
growth and development of VPT neonates.
Development and evolution of iNeo
The initial iNeo collaboration comprised 7 datasets from 
8 countries, which included Australia and New Zealand 
(as one network), Canada, Israel, Japan, Spain, Sweden, 
and the UK Neonatal Collaborative (26). The directors/
custodians of these networks/datasets got together at a 
face-to-face meeting in 2012 to explore the feasibility 
of the collaboration and how to operationalize the idea. 
Conceptualizing iNeo was a smooth process; however, 
we noted many operationalization challenges. After much 
discussion, the protocol for this initiative was developed 
and published (27). Subsequently, we added Finland, 
Switzerland and the Tuscany region of Italy as full members 
of iNeo bringing the current total to 10 networks/datasets 
from 11 countries. There have been 3 full-team face-to-face 
meetings where the development of a minimum dataset, 
modification of the dataset, analytical plans and results were 
discussed. Our initial goal was to combine VPT and VLBW 
neonates (birthweight <1,500 grams) as our base population 
because of the variability of population criteria used by the 
networks. However, following our discussions, iNeo now 
only includes VPT neonates in order to avoid severely 
growth restricted neonates of high gestational age (GA) 
in the dataset. The central coordination center for iNeo 
houses all data and is located in Toronto, Ontario, Canada. 
Further exploration is needed to determine whether a 
concept like distributed-data analyses can be applied to 
allow other countries to have data access. 
Aims and achievements of iNeo
The collaboration was built with several aims, which we 
highlight here while describing what iNeo has achieved and 
what is planned for the future. 
Aim 1: compare national neonatal outcomes and health 
service organization for VPT neonates 
National comparisons of neonatal outcomes and health 
service organizations have been the primary aim of the 
iNeo from the outset. The strategy stemmed from a group 
of studies that each reported comparisons between network 
outcomes of two countries (22-24,27,28) and culminated in 
the first ever comparison of outcomes from 9 countries (26). 
Our key finding was that there are marked variations in 
adverse outcome rates between countries and none of 
the participating countries has the best outcomes for all 
morbidities. A composite outcome of neonatal mortality 
or morbidities varied from 26% to 42% across countries; 
however, when confounders were adjusted, two countries 
had higher standardized rates, two countries had no 
difference in standardized rates and four countries had 
lower standardized rates than the other countries (26). 
We speculated that these differences could be a result of 
population characteristics, data collection mechanisms, 
societal factors, healthcare organization factors, cultural 
factors and practice differences. Untangling composite 
outcome factors further, we assessed differences in mortality 
among neonates born at 24–30 weeks’ GA and reported that 
the survival rate at specific GAs varied between countries; 
in particular, at 24 weeks’ GA survival varied from ~35% to 
84% between countries (29). Similar to mortality, the rates 
of any ROP varied markedly between networks, especially 
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the rates of treated ROP varied between 4% to 30% 
between countries (30). Further evaluation of the variation 
in rates of sepsis (31), NEC (32), and severe brain injury (33) 
between countries/datasets are underway. 
The iNeo database contains information on >200,000 
VPT infants, a population size that has allowed us to 
evaluate the association between exposure to risk factors 
and neonatal outcomes with a very high precision and 
especially study rare exposures such as severe congenital 
heart defects (34). For example, we identified that 
maternal diabetes was not associated with composite 
adverse outcome of mortality or major morbidities in 
VPT neonates (35), and that triplets of <29 weeks’ GA 
had similar outcomes to singletons of <29 weeks’ GA (36). 
In contrast, preterm neonates of <29 weeks GA born to 
mothers with hypertensive disorder were associated with 
lower odds of mortality, severe brain injury and treated 
ROP and higher odds of BPD than preterm neonates 
of <29 weeks GA born to normotensive mothers (37). 
These associations were, however, highly variable between 
countries suggesting that we need large datasets to 
improve the precision of our estimates and the need for 
network collaborations to generate such large datasets.
Aim 2: identify differences in site-level physical, human, 
and environmental characteristics, as well as care practices 
that underlie variations in outcomes
Outcome differences between countries could be a result of 
variability in care practices as many others have explored; 
however, the iNeo collaboration hypothesized that the 
outcome differences could also be a result of site-level 
physical, human-power, and environmental factors. To 
identify such variations, a carefully designed, pre-piloted 
survey with 67 questions (needing 35–45 minutes to 
complete) was circulated to 390 institutions participating 
in iNeo. The survey asked about clinical care practices 
as well as unit-level physical, human, and environmental 
characteristics as they were in the year 2015. The 
respondents were also instructed to reply based on unit-
level practices and not personal preference. The survey was 
circulated in 2016 and closed after 3 rounds of reminders. 
None of the questions were mandatory. A total of 329 (84%) 
units responded to the survey making this a very high-
response survey. We identified marked variations in how 
perinatal-neonatal services are organized between countries 
participating in iNeo (38), despite the fact that most of the 
countries have a publicly-funded healthcare system. 
The differences identified in various surveys can explain 
some of differences in outcomes; however, some of the 
variability merely reflects different ways of providing 
care. There was variations identified in the respiratory 
management of neonates of 23–29 weeks’ GA who were on 
continuous positive airway pressure support and receiving 
30–39% oxygen with some units tolerate high oxygen need 
and continue CPAP, whereas some units utilize practice 
of intubate, administer surfactant and extubate (39). It is 
conceivable that this could explain the variations in the BPD 
rate between countries (40). In order to understand variations 
in BPD and ROP, the iNeo survey asked about oxygen 
saturation limits and determined that >60% of units recently 
increased their oxygen saturation targets (41) based on 
recent trial results. The survey also evaluated other practice 
variations including probiotic use, feeding practices and 
other risk factors of NEC (42); approach to redirecting care 
of critically-ill neonates (43); delivery-room deaths across 
countries (44); screening and treatment criteria for ROP (41); 
and preventative measures for severe brain injury (45). 
Finally, we surveyed the physical layout, facilities available, 
visiting policies (46), and staffing available (47) and identified 
significant variations between units and countries. 
Our next phase of understanding the reasons for 
differences in outcomes is by linking the survey responses 
to actual practices and outcomes from individual units 
and to understand whether any of the practice differences 
are associated with outcomes or not. These analyses 
are ongoing and preliminary results are hypothesis 
generating. We identified that there is marked variations 
in implementation of proposed NEC prevention practices; 
however, there was no relationship of implementation of 
these practices with unit rates of surgical NEC (48). More 
work is needed to continue evaluating changes in practices 
and factors associated with improvement in outcomes.
Aim 3: identify clinical and organizational practice 
improvements relevant to each network
Prior to our multi-country outcomes comparison, individual 
countries had no idea as to how their outcomes compared 
with other countries. The results of our first multi-country 
comparison generated a lot of interest among the participants, 
which led to several teleconferences and face-to-face meetings 
to exchange ideas, practices and unit organization and identify 
potential improvements for local implementation. Several 
teams of iNeo investigators have visited other collaborating 
countries to learn and share their knowledge. 
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More recently, we investigated changes in outcome trends 
between 2007 and 2015 in iNeo countries to identify areas 
for improvement. Consistent outcome improvement was 
observed in a few countries, a static trend in some countries 
and worsening outcomes in others (49). The differences 
in outcome trends were hypothesized to be the result of 
similar factors as described above; however, this challenged 
us to think beyond those factors as trend evaluation within a 
country implies those factors being constant.
Aim 4: implement and continually evaluate the impact 
of data-informed and evidence-linked clinical and 
organizational practice changes in NICUs within 
participating networks 
Identification of outcomes trends in iNeo countries enabled 
us to focus first on identifying harmonized definitions for 
commonly used terminologies in neonates. In collaborations 
with the International Neonatal Consortium and e-Newborn 
initiative, a white paper has been produced identifying the 
need for harmonized definitions. We are also engaged in 
further work for standardization of terminology (50). A 
second step will be to develop a data-informed method of 
identifying clinical and organizational practices that may be 
associated with improved efficiency and outcomes. This work 
has only just begun in a few countries; however, discussions 
are ongoing.
Aim 5: train and mentor junior researchers in the conduct 
of Neonatal-Perinatal health services research
Training and mentoring junior researchers have been key 
objectives of iNeo collaboration. Since the inception of 
iNeo, we have trained 2 post-doctoral fellows, 3 doctoral 
candidates, 1 master’s level researcher, 2 master’s candidates, 
3 post-MD fellows and 1 pre-medical student who all 
have been successful in completing one project each and 
publishing it in reputable journals. The training has been 
open to international trainees and more trainees will be 
accommodated as we continue to accrue more data.
iNeo research methods in brief
Participation
The following neonatal networks are currently participating 
in the iNeo collaboration: Australian and New Zealand 
Neonatal Network (ANZNN, 29 units), Canadian Neonatal 
Network (CNN, 30 units), Finnish Medical Birth Register 
(FinMBR, 5 units), Israeli Neonatal Network (INN, 
27 units), Neonatal Research Network of Japan (NRNJ, 
73 units), Spanish Neonatal Network (SEN1500, 46 units), 
Swedish Neonatal Quality register (SNQ, 37 units), Swiss 
Neonatal Network (SNN, 9 NICU), Tuscany region of 
Italy (TIN Toscane on-line, 4 units) and the UK Neonatal 
Collaborative (UKNC, 131 units) (Table 1, Appendix 1). All 
the participating networks collect, analyze, and benchmark 
the performance and outcomes of their units. Furthermore, 
to obtain robust population-based estimates, we carefully 
avoided networks that only included highly specialized units. 
Development of a minimum dataset
A minimum dataset was created at the iNeo planning 
meeting in July, 2012 after a detailed review of all the 
data items collected the eight original participating 
networks—the elements common to all networks (e.g., 
gestational age, birth weight, sex, etc.) were selected for the 
minimum dataset (Appendix 2). Variations in definitions 
were harmonized for inclusion in the minimum database 
and were mapped to the International Classification of 
Diseases and Related Health Problems (ICD-10) (51) and 
Systematized Nomenclature of Medicine (SNOMED) (52) 
dictionaries.  To ensure consistency and facil itate 
comparisons over time, some networks redefined their 
original data formats as part of an ongoing process, while 
other networks extract data from their databases following 
the iNeo definitions. Currently, all networks/countries have 
provided data from 2007–2016 to the coordinating center. 
The collection items were increased recently to reflect 
changes in care provision to VPT neonates. New data will 
only include data from 2017. 
Outcomes
The main outcomes of interest for the iNeo collaboration 
are the following:  
 Mortality: death prior to discharge from NICU;
 Severe  neurologica l  in jury  (53) :  de f ined  as 
intraventricular hemorrhage with ventricular dilatation, 
or parenchymal injury [including periventricular 
leukomalacia (PVL) with or without intraventricular 
hemorrhage];
 Stage 2 or 3 NEC (54): based on modified Bell’s 
criteria; 
 Severe ROP (55): defined as stage 3 or 4 ROP, or need 
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for laser surgery, or intraocular injections of anti-
vascular endothelial growth factor agents;
 NI (56): defined as culture proven sepsis (blood or 
cerebrospinal fluid positive for pathogenic organism) 
after 2 days of postnatal age; 
 BPD (57): defined as oxygen requirement at 36 weeks 
post-menstrual age. 
These morbidities are associated with an increased 
risk of long-term severe neurodevelopmental impairment 
(odds ratios of 1.5 to 3.0) (58). Various studies have shown 
these morbidities to be predictors of long-term adverse 
outcomes (59). We are also interested in other outcomes 
such as patent ductus arteriosus requiring surgical ligation, 
receipt of delivery room cardiopulmonary resuscitation, air 
leak syndrome, and resource utilization (length of stay and 
length of respiratory support).
Analytical framework 
(I) Descriptive analyses of  basel ine factors:  the 
distribution of neonate characteristics and country-
level broad organizational structural features are 
summarized as counts and percentages for categorical 
variables using the mean and standard deviation, or 
the median and interquartile range for continuous 
variables, and compared among all networks using the 
Chi-square test for categorical and ANOVA F-test or 
Mood’s median test for continuous variables. 
(II) Statistical comparisons of outcomes between 
networks: for the adverse outcomes analyses, initial 
crude rates and associated 95% and 99% confidence 
intervals are calculated and graphically displayed 
using ‘caterpillar plots’ to visually identify differences 
between networks. To adjust for multiple baseline 
characteristics, standardized mortality/morbidity 
ratios (SMRs) are computed using the ‘indirect 
standardization’ approach. Each network’s observed 
rate is compared with the expected rate based on 
the total sample from all other networks to identify 
networks with rates significantly above or below 
average. For each outcome, the expected number 
of events is computed as the sum of predicted 
probabilities from a multivariable model (logistic 
regression or zero inflated negative binomial models 
based on data distribution) adjusted for confounders. 
Network SMR are graphically displayed using ‘funnel’ 
plots with 95% and 99% prediction intervals for 
comparison between networks. In addition, pair-wise 
comparisons between specific networks with high- and 
low-outcome rates are performed using multivariate 
models adjusted for confounders. Statistical models 
employ generalized estimating equations to adjust 
analyses for clustering of neonates within networks 
and for multiples. Statistical significance is evaluated 
by applying a Bonferroni correction to account for 
multiple pair-wise comparisons. 
Program administration
The day-to-day management of the iNeo collaboration is 
overseen by the iNeo Director while a Steering Committee 
comprising of one or two members from each country 
assesses the overall progress of iNeo, evaluates the scientific 
merits of proposed projects, reviews results, identifies and 
articulates strengths and limitations of analyses, and recruits 
and trains junior researchers interested in international 
neonatal health. The Director is supported by the iNeo 
Program Coordinator and a dedicated statistician. The iNeo 
Coordinating Centre is housed at the Maternal-Infant Care 
Research Centre (MiCare) within the Samuel Lunenfeld 
Research Institute at Mount Sinai Hospital, Toronto. Each 
national data coordinating centre is responsible for local 
data processing, extraction, transfer, and dissemination of 
findings to their respective sites. 
Financial support for the iNeo coordinating center is 
provided by an Applied Research Chair Grant from the 
IHDCYH, CIHR and the infrastructure of individual 
networks is supported by their own budgets (Appendix 3). 
The individual network coordinating centres also act as 
local training sites for trainees in Health Services Research 
in Neonatal-Perinatal Medicine. In order to foster a true 
international collaboration, the data collected and housed 
at the iNeo Coordinating Centre are available to all iNeo 
member countries and iNeo-affiliated investigators. The 
policies and procedures governing the transfer of data 
between national data centres are guided by specific data 
sharing agreements signed by all participants and their 
institutes (Appendix 4).
All networks/data custodians have obtained ethics/
regulatory approval or its equivalent from their local 
granting agencies to allow for de-identified data to be 
collated and sent to the iNeo Coordinating Centre. Overall 
coordination of the project is also approved by the Research 
Ethics Board at the Mount Sinai Hospital, Toronto, Ontario 
Canada for the development, compilation, hosting and 
management of the iNeo dataset at the MiCare Research 
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Centre. Privacy and confidentiality are of utmost iNeo 
importance to the iNeo collaboration, and as such data is 
handled in accordance with the Privacy Commissioner’s 
guidelines. 
Manuscripts published as a result of projects arising 
from the iNeo collaboration follow the iNeo publication 
principles (Appendix 5), and all publications have “on behalf 
of iNeo” as the final author. The remaining publication 
principles govern data requests and approval, data transfer 
and analyses, and approval of manuscripts and publications.
Lessons learned 
The evolution of iNeo has taught us all critical lessons 
about the establishment of international collaborations; 
similarities and differences in healthcare systems, resources, 
and operations; and variations in outcomes including the 
following:
(I) Working with the legal or contracts office at each 
data hosting institution is critical to overcome 
systems-associated challenges when establishing 
international collaborations;
(II) Privacy and conf ident ia l i ty  are  of  utmost 
importance when handling healthcare related data, 
and it is essential to follow all necessary steps to 
protect the information;
(III) Collaborative approaches involving all participating 
parties can lead to a very fruitful harmonization;
(IV) Everyone should be willing to accept their 
deficiencies, learn from others and teach others at the 
same time;
(V) Allowing data access to all participating countries 
has many administrative hurdles, including 
financial support; however, when the processes 
are incorporated into the collaborative model it 
facilitates the data sharing process;
(VI) Large collaborations require buy-in from local 
units; in particular, local units need to understand 
the contribution of their data to the greater good 
and the importance of access to large data pools 
for answering questions with a higher degree of 
certainty.
Future plans
Future plans for iNeo include the following:
(I) Expansion of network: the success of iNeo has sparked 
the interest of several other countries who would like 
to participate as well. Norway, Taiwan, South Korea, 
and California in the USA have all expressed interest 
discussions have begun to potentially add them to the 
collaboration. In addition, one large unit in Singapore 
and two in Hong Kong are currently submitting data 
to the Australian and New Zealand Neonatal Network 
(ANZNN). More Singapore and Hong Kong units 
are anticipated to contribute data from 2020. Given 
the global interest in iNeo, we are expecting that the 
collaboration will expand to include more countries 
over the next 2 years.
(II) Harmonization of data collection across networks: 
members of  iNeo are collaborating with the 
International Neonatal Consortium (INC) to 
harmonize data collection of common neonatal 
conditions, demographic characteristics and diagnoses. 
The plan is to develop measurable and impactful 
criteria for use in benchmarking, quality improvement 
activities and research over the next 2 years. Participants 
of iNeo have published papers on the harmonization of 
definitions for both BPD (40) and NEC (60), and we 
aim to develop recommendations for other diagnoses 
related to VPT neonates over the next 2 years. 
(III) Dissemination of data collection tools to networks in 
Low-Middle Income countries: one goal of iNeo is to 
help develop benchmarking capacity in Low-Middle 
Income Countries. For this reason, we have shared 
our minimal database with several NICU in India 
and China (where 60 units are collecting data using a 
similar format), which will allow them to benchmark 
and compare their outcomes among themselves and 
internationally.
(IV) International neonatal follow-up network: There 
is a growing interest among iNeo countries to 
compare 2–3 years neurodevelopmental outcome 
data for the extremely preterm (<28 weeks GA) 
neonates. However, networks and countries use 
different instruments to collect neurodevelopmental 
outcomes data. To address this problem, iNeo is in 
the beginning stages of creating a tool to measure 
the equivalency of outcomes assessed using different 
instruments. The tool may not result in perfect data 
harmonization; however, we hope to discover some 
patterns that can be investigated further. 
(V) Development and execution of network-based clinical 
trials: to further improve VPT outcomes, high-quality, 
evidence-informed therapies are needed. However, 
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evidence for new therapies usually comes from large 
randomized trials, which are time consuming and 
expensive to conduct. Established networks can 
facilitate point-of-care trials (61) by linking trial data 
collection to routine network-level data collection and 
acting as a conduit for identifying eligible patients, 
both of which significantly reduce trial cost. 
(VI) Collaborative quality improvement activities: the 
greatest impact any data collection project can have 
is when data are converted to information and action. 
For example, multiple networks have reported 
successful neonatal outcome improvement through 
data-driven quality improvement efforts (62-66). 
However, many of the iNeo countries do not have 
established national/regional quality improvement 
programs that use their network data. For these 
networks, the next goal is to learn from networks with 
established quality improvement programs and use 
the experience to establish a national/regional quality 
improvement program in their home countries.
Conclusions
The iNeo collaboration serves as a strong international 
platform for Neonatal-Perinatal health services research 
for VPT neonates. The data generated by iNeo continues 
to provide neonatal benchmarking standards for each 
country and unit, which will hopefully lead to detailed 
discussion on how to improve outcomes for VPT neonates 
globally. Simultaneous capacity building by training junior 
researchers continues be an added benefit.
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Appendix 1 iNeo networks and investigators
ANZNN (Australian and New Zealand Neonatal 
Network): Kei Lui* Chair of ANZNN. Flinders Medical 
Centre, SA: Peter Marshall. Gold Coast University 
Hospital, QLD: Peter Schmidt. Blacktown District 
Hospital, NSW: Anjali Dhawan*. John Hunter Children’s 
Hospital, NSW: Paul Craven, Koert de Waal*. King 
Edward Memorial and Perth Children’s Hospitals, WA: 
Karen Simmer, Andy Gill*, Jane Pillow*. Liverpool 
Hospital, NSW: Jacqueline Stack. Mater Mothers’ Hospital, 
QLD: Pita Birch, Neonatal Retrieval Service, QLD: Lucy 
Cooke*. Mercy Hospital for Women, VIC: Dan Casalaz, 
Jim Holberton*. Monash Medical Centre, VIC: Alice 
Stewart. Nepean Hospital, NSW: Lyn Downe. Newborn 
Emergency Transport Service (VIC): Michael Stewart. 
NSW Pregnancy and Newborn Services Network: Barbara 
Bajuk*. NSW Newborn & Paediatric Emergency Transport 
Service: Andrew Berry. Royal Children’s Hospital, VIC: Rod 
Hunt. Royal Darwin Hospital, NT: Charles Kilburn. Royal 
Hobart Hospital, Tasmania: Tony De Paoli. Royal Hospital 
for Women, NSW: Kei Lui*, Srinivas Bolisetty. Royal 
North Shore Hospital, NSW: Mary Paradisis. Royal Prince 
Alfred Hospital, NSW: Ingrid Rieger. Royal Brisbane and 
Women’s Hospital, QLD: Pieter Koorts. Royal Women’s 
Hospital, VIC: Carl Kuschel, Lex Doyle. Sydney Children’s 
Hospital, NSW: Andrew Numa. The Canberra Hospital, 
ACT: Hazel Carlisle. The Children’s Hospital at Westmead, 
NSW: Nadia Badawi, Alison Loughran-Fowlds. The 
Townsville Hospital, QLD: Guan Koh. Western Australia 
Neonatal Transport Service: Jonathan Davis. Westmead 
Hospital, NSW: Melissa Luig. Women’s & Children’s 
Hospital, SA: Chad Andersen*. National Perinatal 
Epidemiology and Statistics Unit, University of New South 
Wales: Georgina Chambers*. New Zealand: Christchurch 
Women’s Hospital: Nicola Austin, Adrienne Lynn. 
University of Otago, Christchurch: Brian Darlow. Dunedin 
Hospital: Liza Edmonds. Middlemore Hospital: Lindsay 
Mildenhall. Auckland City Hospital: Mariam Buksh, 
Malcolm Battin*. North Shore and Waitakere Hospitals: 
Jutta van den Boom*. Waikato Hospital: David Bourchier. 
Wellington Women’s Hospital: Vaughan Richardson, Fiona 
Dineen*. Singapore: KK Women’s and Children’s Hospital, 
Singapore: Victor Samuel Rajadurai*. Hong Kong: Prince 
of Wales Hospital: Simon Lam. United Christian Hospital: 
Genevieve Fung. 
CNN (Canadian Neonatal Network): Prakesh S 
Shah, MD, MSc (Director, Canadian Neonatal Network 
and site investigator), Mount Sinai Hospital, Toronto, 
Ontario; Adele Harrison, MD, MBChB, Victoria General 
Hospital, Victoria, British Columbia; Anne Synnes, 
MDCM, MHSC, and Joseph Ting, MD, B.C. Women’s 
Hospital and Health Centre, Vancouver, British Columbia; 
Zenon Cieslak, MD, Royal Columbian Hospital, New 
Westminster, British Columbia; Rebecca Sherlock, MD, 
Surrey Memorial Hospital, Surrey, British Columbia; 
Wendy Yee, MD, Foothills Medical Centre, Calgary, 
Alberta; Khalid Aziz, MBBS, MA, MEd, and Jennifer Toye, 
MD, Royal Alexandra Hospital, Edmonton, Alberta; Carlos 
Fajardo, MD, Alberta Children’s Hospital, Calgary, Alberta; 
Zarin Kalapesi, MD, Regina General Hospital, Regina, 
Saskatchewan; Koravangattu Sankaran, MD, MBBS, and 
Sibasis Daspal, MD, Royal University Hospital, Saskatoon, 
Saskatchewan; Mary Seshia, MBChB, Winnipeg Health 
Sciences Centre, Winnipeg, Manitoba; Ruben Alvaro, 
MD, St. Boniface General Hospital, Winnipeg, Manitoba; 
Amit Mukerji, MD, Hamilton Health Sciences Centre, 
Hamilton, Ontario; Orlando Da Silva, MD, MSc, London 
Health Sciences Centre, London, Ontario; Chuks Nwaesei, 
MD, Windsor Regional Hospital, Windsor, Ontario; 
Kyong-Soon Lee, MD, MSc, Hospital for Sick Children, 
Toronto, Ontario; Michael Dunn, MD, Sunnybrook Health 
Sciences Centre, Toronto, Ontario; Brigitte Lemyre, MD, 
Children’s Hospital of Eastern Ontario and Ottawa General 
Hospital, Ottawa, Ontario; Kimberly Dow, MD, Kingston 
General Hospital, Kingston, Ontario; Ermelinda Pelausa, 
MD, Jewish General Hospital, Montréal, Québec; Keith 
Barrington, MBChB, Hôpital Sainte-Justine, Montréal, 
Québec; Christine Drolet, MD, and Bruno Piedboeuf, 
MD, Centre Hospitalier Universitaire de Québec, Sainte 
Foy Québec; Martine Claveau, MSc, LLM, NNP, and 
Marc Beltempo, MD, McGill University Health Centre, 
Montréal, Québec; Valerie Bertelle, MD, and Edith Masse, 
MD, Centre Hospitalier Universitaire de Sherbrooke, 
Sherbrooke, Québec; Roderick Canning, MD, Moncton 
Hospital, Moncton, New Brunswick; Hala Makary, MD, Dr. 
Everett Chalmers Hospital, Fredericton, New Brunswick; 
Cecil Ojah, MBBS, and Luis Monterrosa, MD, Saint John 
Regional Hospital, Saint John, New Brunswick; Akhil 
Deshpandey, MBBS, MRCPI, Janeway Children’s Health 
and Rehabilitation Centre, St. John’s, Newfoundland; Jehier 
Afifi, MB BCh, MSc, IWK Health Centre, Halifax, Nova 
 
*, denotes the ANZNN Executive Committee.
Scotia; Andrzej Kajetanowicz, MD, Cape Breton Regional 
Hospital, Sydney, Nova Scotia; Shoo K Lee, MBBS, PhD 
(Chairman, Canadian Neonatal Network), Mount Sinai 
Hospital, Toronto, Ontario.
FinMBR (Finnish Medical Birth Register): Sture 
Andersson, MD, Helsinki University Hospital, Helsinki; 
Liisa Lehtonen, MD, Turku University Hospital, Turku; 
Outi Tammela, MD, Tampere University Hospital, 
Tampere; Ulla Sankilampi, MD, Kuopio University 
Hospital, Kuopio; Timo Saarela, MD, Oulu University 
Hospital, Oulu.
ILL (Illinois Neonatal Network): Preetha Prazad, 
MD, Advocate Children’s Hospital, Park Ridge, Illinois; 
Akihiko Noguchi, MD, SSM Cardinal Glennon/St. Mary’s 
Hospital, St. Louis MO; Kamlesh McWan, MD, Children’s 
Hospital of Illinois, Peoria, Illinois; Beau Button, MD, St 
John’s Hospital, Springfield, Illinois; William Stratton, 
MD, Carle Foundation Hospital, Urbana, Illinois; Aaron 
Hamvus, MD, Northwestern University Hospitals, 
Chicago, Illinois; Aarti Raghaven, MD, University Illinois 
Chicago Hospital, Chicago, Illinois; Matthew Derrick, MD, 
Evanston Northshore Hospital, Evanston, Illinois; Radley 
Hadley, MD, Advocate Illinois Masonic Hospital, Chicago, 
Illinois; Robert Covert, MD, Edward Hospital, Naperville, 
Illinois; Omar Lablanc, MD, John H. Stroger Cook County 
Hospital, Chicago, Illinois; Marc Weiss, MD, RMCH 
Loyola University Hospital, Maywood, Illinois; Anthony 
Bell, MD, Adventist Hinsdale Hospital, Hinsdale, Illinois; 
Maliha Shareef, MD, St. Alexius Hospital, Hoffman Estates, 
Illinois; Jean Silvestri, MD, Rush University Hospital, 
Chicago, Illinois.
INN (Israel Neonatal Network): Eli Heymann, 
MD, Assaf Harofeh Medical Center, Tzrifin; Shmuel 
Zangen, MD, Barzilai Medical Center, Ashkelon; Tatyana 
Smolkin, MD, Baruch Padeh Medical Center, Poriya; 
Francis Mimouni, MD, Bikur Cholim Hospital, Jerusalem; 
David Bader, MD, Bnai Zion Medical Center, Haifa; Avi 
Rothschild, MD, Carmel Medical Center, Haifa; Zipora 
Strauss, Chaim Sheba Medical Center, Ramat Gan; Clari 
Felszer, MD, Emek Medical Center, Afula; Hussam 
Omari, MD,  French Saint Vincent de Paul Hospital, 
Nazareth; Smadar Even Tov-Friedman, MD, Hadassah 
University Hospital-Ein Karem, Jerusalem; Benjamin Bar-
Oz, MD, Hadassah University Hospital-Har Hazofim, 
Jerusalem; Michael Feldman, MD, Hillel Yaffe Medical 
Center, Hadera; Nizar Saad, MD, Holy Family (Italian) 
Hospital, Nazareth; Orna Flidel-Rimon, MD, Kaplan 
Medical Center, Rehovot; Meir Weisbrod, MD, Laniado 
Hospital, Netanya; Daniel Lubin, MD, Mayanei Hayeshua 
Medical Center, Bnei Brak; Ita Litmanovitz, MD, Meir 
Medical Center, Kfar Saba; Amir Kugelman, MD, Rambam 
Medical Center; Eric Shinwell, MD, Rivka Ziv Medical 
Center, Safed; Gil Klinger, MD, Schneider Children’s 
Medical Center of Israel, Rabin Medical Center (Beilinson 
Campus), Petah Tikva; Yousif Nijim, MD,  Scottish 
(EMMS) Hospital, Nazareth; Alona Bin-Nun, MD, 
Shaare-Zedek Medical Center, Jerusalem; Agneta Golan, 
MD, Soroka Medical Center, Beersheba; Dror Mandel, 
MD, Sourasky Medical Center, Tel Aviv; Vered Fleisher-
Sheffer, MD,Western Galilee Medical Center, Nahariya; 
David Kohelet, MD, Wolfson Medical Center, Holon; Lev 
Bakhrakh, MD, Yoseftal Hospital, Eilat.
NRNJ (Neonatal Research Network Japan): Satoshi 
Hattori, MD, Sapporo City Hospital, Sapporo, Hokkaido; 
Masaru Shirai, MD, Asahikawa Kosei Hospital, Asahikawa, 
Hokkaido; Toru Ishioka, MD, Engaru Kosei Hospital, 
Engaru, Hokkaido; Toshihiko Mori, MD, NTT East 
Sappro Hospital, Sapporo, Hokkaido; Takasuke Amizuka, 
MD, Aomori Prefecture Central Hospital, Aomori, Aomori; 
Toru Huchimukai, MD, Iwate Prefecture Ohfunato 
Hospital, Ofunato, Iwate; Hiroshi Yoshida, MD, Tsuruoka 
City Shonai Hospital, Tsuruoka, Yamagata; Ayako Sasaki, 
MD, Yamagata University, Yamagata, Yamagata; Junichi 
Shimizu, MD, Tsuchiura Kyodo Hospital, Tsuchiura, 
Ibaraki; Toshihiko Nakamura, MD, National Nishisaitama 
Central Hospital, Tokorozawa, Saitama; Mami Maruyama, 
MD, Jichi Medical University Saitame Medical Center, 
Omiya, Saitama; Hiroshi Matsumoto, MD, Asahi Central 
Hospital, Asahi, Chiba; Shinichi Hosokawa, MD, National 
International Medical Center, Shinjuku, Tokyo; Atsuko 
Taki, MD, Tokyo Medical and Dental University, Bunkyo, 
Tokyo; Machiko Nakagawa, MD, Saint Luku Hospital, 
Chuo, Tokyo; Kyone Ko, MD, Sanikukai Hospital, Sumida, 
Tokyo; Azusa Uozumi, MD, Odawara City Hospital, 
Odawara, Kanagawa; Setsuko Nakata, MD, Iida City 
Hospital, Iida, Nagano; Akira Shimazaki, MD, National 
Shinshu Ueda Medical Center, Ueda, Nagano; Tatsuya 
Yoda, MD, Saku General Hospital, Saku, Nagano; Osamu 
Numata, MD, Nagaoka Red Cross Hospital, Nagaoka, 
Niigata; Hiroaki Imamura, MD, Koseiren Takaoka 
Hospital, Takaoka, Toyama; Azusa Kobayashi, MD, 
Kanazawa Medical University, Kanazawa, Kanazawa; Shuko 
Tokuriki, MD, Fukui University, Fukui, Fukui; Yasushi 
Uchida, MD, National Nagara Medical Center, Nagara, 
Gifu; Takahiro Arai, MD, Takayama Red Cross Hospital, 
Takayama, Gifu; Mitsuhiro Ito, MD, Fujieda City Hospital, 
Fujieda, Shizuoka; Kuniko Ieda, MD, Koritsu Tosei 
Hospital, Toyota, Aichi; Toshiyuki Ono, MD, Komaki City 
Hospital, Komaki, Aichi; Masashi Hayashi, MD, Okazaki 
City Hospital, Okazaki, Aichi; Kanemasa Maki, MD, 
Yokkaichi City Hospital, Yokkaichi, MieToru Yamakawa, 
MD, Japan Baptist Hospital, Kyoto, Kyoto; Masahiko 
Kawai, MD, Kyoto University, Kyoto, Kyoto; Noriko Fujii, 
MD, Fukuchiyama City Hospital, Fukuchiyama, Kyoto; 
Kozue Shiomi, MD, Kyoto City Hospital, Kyoto, Kyoto; 
Koji Nozaki, MD, Mitubishi Kyoto Hospital, Kyoto, 
Kyoto; Hiroshi Wada, MD, Yodogawa Christian Hospital, 
Osaka, Osaka; Taho Kim, MD, Osaka City Sumiyoshi 
Hospital, Osaka, Osaka; Yasuyuki Tokunaga, MD, Toyonaka 
City Hospital, Toyonaka, Osaka; , MD, National Cerebral 
and Cardiovascular Center, Suita, Osaka; Akihiro Takatera, 
MD, Chifune Hospital, Osaka, Osaka; Toshio Oshima, 
MD, Bell Land General Hospital, Sakai, Osaka; Hiroshi 
Sumida, MD, Rinku General Hospital, Izumisano, Osaka; 
Yae Michinomae, MD, Yao City Hospital, Yao, Osaka; 
Yoshio Kusumoto, MD, Osaka General Medical Center, 
Osaka, Osaka; Seiji Yoshimoto, MD, Kobe Children’s 
Hospital, Kobe, Hyogo; Takeshi Morisawa, MD, Kakogawa 
City Hospital, Kakogawa, Hyogo; Tamaki Ohashi, MD, 
Hyogo Prefectural Awaji Hospital, Sumoto, Hyogo; 
Yukihiro Takahashi, MD, Nara Prefecture Medical 
University, Kashiwara, Nara; Moriharu Sugimoto, MD, 
Tsuyama Central Hospital, Tsuyama, Okayama; Noriaki 
Ono, MD, Hiroshima University, Hiroshima, Hiroshima; 
Shinichiro Miyagawa, MD, National Kure Medical 
Center, Kure, Hiroshima; Takahiko Saijo, MD, Tokushima 
University, Tokushima, Tokushima; Takashi Yamagami, 
MD, Tokushima City Hospital, Tokushima, Tokushima; 
Kosuke Koyano, MD, Kagawa University, Kida, Kagawa; 
Shoko Kobayashi, MD, Shikoku Medical Center for 
Children and Adults, Zentsuji, Kagawa; Takeshi Kanda, 
MD, National Kyushu Medical Center, Fukuoka, Fukuoka; 
Yoshihiro Sakemi, MD, National Kokura Medical Center, 
Kitakyushu, Fukuoka; Mikio Aoki, MD, National Nagasaki 
Medical Center, Nagasaki, Nagasaki; Koichi Iida, MD, 
Oita Prefectural Hospital, Oita, Oita; Mitsushi Goshi, MD, 
Nakatsu City Hospital, Nakatsu, Oita; Yuko Maruyama, 
MD, Imakyure General Hospital, Kagoshima, Kagoshima.
SEN1500 (Spanish Neonatal Network): Alejandro 
Avila-Alvarez, MD, and José Luis Fernandez-Trisac, MD, 
Complexo Hospitalario  Universitario De A Coruña, 
A Coruña; Mª Luz Couce Pico, MD, and María  José 
Fernández Seara, MD, Hospital Clínico Universitario 
de Santiago, Santiago de Compostela; Andrés Martínez 
Gutiérrez, MD, Complejo Hospitalario Albacete, Albacete; 
Carolina Vizcaíno ,  MD, Hospital General Universitario 
de Elche, Alicante;  Miriam Salvador Iglesias, MD, 
and Honorio Sánchez Zaplana, MD, Hospital General 
Universitario  de Alicante, Alicante; Belén Fernández 
Colomer, MD, and José Enrique García  López, MD, 
Hospital Universitario Central de Asturias, Oviedo, Asturias; 
Rafael García  Mozo, MD, and M. Teresa González 
Martínez, MD, Hospital Universitario de Cabueñes,  Gijón, 
Asturias; Mª Dolores Muro Sebastián, MD, and Marta 
Balart Carbonell, MD, Clínica Corachán, Barcelona; Joan 
Badia Barnusell, MD, and Mònica Domingo Puiggròs,  MD, 
Corporacio Parc Taulí, Sabadell, Barcelona; Josep Figueras 
Aloy, MD, and Francesc Botet  Mussons, MD, Hospital 
Clínic de Barcelona, Barcelona; Israel Anquela Sanz, MD, 
Hospitalario De Granollers, Granollers; Gemma Ginovart 
Galiana, MD, H. De La  Santa Creu I Sant Pau, Barcelona; 
W. Coroleu, MD, Hospital Universitari Germans  Trias I 
Pujol, Badalona; Martin Iriondo, MD, Hospital Sant Joan 
de Déu  Barcelona, Esplugues de Llobregat, Barcelona; 
Laura Castells Vilella, MD, Hospital General de  Cataluña, 
Barcelona; Roser Porta, MD, Institute Dexeus,  Barcelona; 
Xavier Demestre, MD, and Silvia Martínez Nadal, MD, 
Scias-Hospital Barcelona, Barcelona; Cristina de Frutos 
Martínez, MD, Hospital Universitario de Burgos, Burgos; 
María Jesús López Cuesta, MD, H. San Pedro de Alcántara, 
Cáceres;  Dolores Esquivel Mora, MD, and Joaquín Ortiz 
Tardío, MD, Hospital Jerez, Cádiz;  Isabel Benavente, MD, 
and Almudena Alonso, MD, Hospital Universitario Puerta 
Del Mar, Cádiz; Ramón Aguilera Olmos, MD, Hospital 
General de Castellón, Castellón; Miguel A. García Cabezas, 
MD, and Mª Dolores Martínez Jiménez, MD,  Hospital 
General Universitario de Ciudad Real, Ciudad Real; Mª 
Pilar Jaraba Caballero,  MD, and Mª Dolores Ordoñez 
Díaz, MD, Hospital Universitario Reina Sofía, Córdoba; 
Alberto Trujillo Fagundo, MD, and Lluis Mayol Canals, 
MD, Hospital Universitari de  Girona Dr. Josep Trueta, 
Girona; Fermín García-Muñoz Rodrigo, MD, and  Lourdes 
Urquía Martí, MD, H.M.I. Las Palmas, Las Palmas, Gran 
Canaria; María Fernanda Moreno  Galdo , MD, and José 
Antonio Hurtado Suazo, MD, Hospital Universitario 
Virgen De Las  Nieves, Granada; Eduardo Narbona López, 
and José Uberos Fernández, MD, Hospital  Universitario 
San Cecilio, Granada; Miguel A Cortajarena Altuna, MD, 
and Oihana  Muga Zuriarrain Hospital, MD,  Donostia, 
Gipuzkoa; David Mora Navarro, MD, Hospital  Juan 
Ramón Jiménez, Huelva; María Teresa Domínguez, MD, 
Hospital Costa De La  Luz, Huelva; Mª Yolanda Ruiz del 
Prado, MD, and Inés Esteban Díez, MD, Hospital  San 
Pedro, Logroño, La Rioja; María Teresa Palau Benavides, 
MD, and Santiago Lapeña,  MD, Hospital de León, León, 
León; Teresa Prada, MD, Hospital del Bierzo, Ponferrada, 
León; Eduard Soler Mir, MD, Hospital Arnau De 
Vilanova, Lleida;  Araceli Corredera Sánchez, MD, Enrique 
Criado Vega, MD,  Náyade del Prado, MD, and Cristina 
Fernández, MD, Hospital Clínico San Carlos, Madrid; 
Lucía Cabanillas Vilaplana,  MD, and Irene Cuadrado 
Pérez, MD, Hospital Universitario De Getafe, Madrid; 
Luisa López  Gómez, MD, Hospital De La Zarzuela, 
Madrid; Laura Domingo Comeche, MD, Hospital 
Universitario de Fuenlabrada, Fuenlabrada, Madrid; Isabel 
Llana Martín, MD, Hospital  Madrid-Torrelodones, 
Madrid, Madrid; Carmen González Armengod, MD, and 
Carmen Muñoz Labián,  MD, Hospital Universitario 
Puerta De Hierro, Majadahonda, Madrid; Mª José Santos 
Muñoz,  MD, Hospital Severo Ochoa, Leganés, Madrid; 
Dorotea Blanco Bravo, MD, and Vicente  Pérez, MD, 
Hospital Gregorio Marañón, Madrid; Mª Dolores Elorza 
Fernández, MD,  Celia Díaz González, MD, and Susana 
Ares  Segura, MD, H.U. La Paz, Madrid; Manuela  López 
Azorín, MD, Hospital Universitario Quirónsalud Madrid, 
Madrid; Ana Belén Jimenez MD, Hospital  Universitario 
Fundación Jiménez Díaz, Madrid; Tomás Sánchez-
Tamayo, MD, and Elías  Tapia Moreno, MD, Hospital 
Carlos Haya, Málaga; María González, MD, and José 
Enrique Sánchez Martínez, MD, Hospital Parque San 
Antonio De Málaga, Málaga; José María Lloreda García, 
MD, Hospital Universitario Santa Lucia De Cartagena, 
Murcia; Concepción Goñi Orayen, MD, Hospital Virgen 
Del Camino De Pamplona, Pamplona,  Navarra; Javier 
Vilas González, MD, Complexo Hospitalario Pontevedra, 
Pontevedra;  María Suárez Albo, MD, and Eva González 
Colmenero, MD, Hospital Xeral De Vigo, Pontevedra; 
Elena Pilar Gutiérrez González, MD, and Beatriz Vacas del 
Arco, MD, Hospital Universitario de Salamanca, Salamanca; 
Josefina Márquez Fernández, MD,  and Laura Acosta 
Gordillo, MD, Hospital Valme, Sevilla; Mercedes  Granero 
Asensio, MD, Hospital Virgen De La Macarena, Sevilla; 
Carmen Macías Díaz,  MD, Hospital Universitario Virgen 
Del Rocío, Sevilla; Mar Albújar, MD, Hospital  Universitari 
de Tarragona Joan XXIII, Tarragona; Pedro Fuster Jorge. 
MD,  Hospital Universitario De Canarias, San Cristóbal de 
La Laguna, Santa Cruz de Tenerife; Sabina  Romero, MD, 
and Mónica Rivero Falero, MD, Hospital Universitario 
Nuestra Señora De  Candelaria, Santa Cruz de Tenerife; 
Ana Belén Escobar Izquierdo,  Hospital Virgen De La 
Salud, Toledo; Javier Estañ Capell, MD, Hospital Clinico 
Universitario De Valencia, Valencia; Mª Isabel Izquierdo 
Macián, MD, Hospital  Universitari La Fe, Valencia; 
Mª Mar Montejo Vicente, MD, and Raquel Izquierdo 
Caballero, MD, Hospital Universitario Río Hortega, 
Valladolid; Mª Mercedes  Martínez, MD, and Aintzane 
Euba, MD, Hospital de Txagorritxu, Vitoria-Gasteiz; 
Amaya  Rodríguez Serna, MD, and Juan María López de 
Heredia Goya, MD, Hospital de Cruces, Baracaldo; Alberto 
Pérez Legorburu, MD, and Ana Gutiérrez Amorós, MD, 
Hospital  Universitario de Basurto, Bilbao; Víctor Manuel 
Marugán Isabel, MD, and Natalio  Hernández González, 
MD, Hospital Virgen De La Concha - Complejo Asistencial 
De Zamora, Zamora; Segundo Rite Gracia, MD, Hospital 
Miguel Servet, Zaragoza; Mª  Purificación Ventura Faci, 
MD, and Mª Pilar Samper Villagrasa, MD, Hospital Clínico 
Universitario  Lozano Blesa, Zaragoza.
SNQ (Swedish Neonatal Quality Register): Jiri 
Kofron, MD, Södra Älvsborgs Sjukhus, Borås; Katarina 
Strand Brodd, MD, Mälarsjukhuset, Eskilstuna; Andreas 
Odlind, MD, Falu Lasarett, Falun; Lars Alberg, MD, 
Gällivare Sjukhus, Gällivare; Sofia Arwehed, MD, Gävle 
Sjukhus, Gävle; Ola Hafström, MD, SU/Östra, Göteborg; 
Anna Kasemo, MD, Länssjukhuset, Halmstad; Karin 
Nederman, MD, Helsingborgs Lasarett, Helsingborg; Lars 
Åhman, MD, Hudiksvalls Sjukhus, Hudiksvall; Fredrik 
Ingemarsson, MD, Länssjukhuset Ryhov, Jönköping; 
Henrik Petersson, MD, Länssjukhuset, Kalmar; Pernilla 
Thurn, MD, Blekingesjukhuset, Karlskrona; Eva Albinsson, 
MD, Centralsjukhuset, Karlstad; Bo Selander, MD, 
Centralsjukhuset, Kristianstad; Thomas Abrahamsson, MD, 
Universitetssjukhuset, Linköping; Ingela Heimdahl, MD, 
Sunderby sjukhus, Luleå; Kristbjorg Sveinsdottir, MD, 
Skånes Universitetssjukhus, Malmö/Lund; Erik Wejryd, 
MD, Vrinnevisjukhuset, Norrköping; Anna Hedlund, MD, 
Skellefteå Lasarett, Skellefteå; Maria Katarina Söderberg, 
MD, Kärnsjukhuset Skaraborg, Skövde; Boubou Hallberg, 
MD, Karolinska Sjukhuset, Stockholm; Thomas Brune, 
MD, Södersjuhuset, Stockholm; Jens Bäckström, MD, 
Länssjukhuset, Sundsvall; Johan Robinson, MD, Norra 
Älvsborgs Länssjukhus, Trollhättan; Aijaz Farooqi, MD, 
Norrlands Universitetssjukhus, Umeå; Erik Normann, 
MD, Akademiska Barnsjukhuset, Uppsala; Magnus 
Fredriksson, MD, Visby Lasarett, Visby; Anders Palm, 
MD, Västerviks Sjukhus, Västervik; Urban Rosenqvist, 
MD, Centrallasarettet, Västerås; Bengt Walde, MD, 
Centrallasarettet, Växjö; Cecilia Hagman, MD, Lasarettet, 
Ystad; Andreas Ohlin, MD, Universitetssjukhuset, Örebro; 
Rein Florell, MD, Örnsköldsviks Sjukhus, Örnsköldsvik; 
Agneta Smedsaas-Löfvenberg, MD, Östersunds Sjukhus, 
Östersund.
Swiss NeoNet (Switzerland Neonatal Network): 
Philipp Meyer, MD, and Claudia Anderegg, MD, Cantonal 
Hospital, Children’s Clinic, Aarau; Sven Schulzke, MD, 
University Children’s Hospital, Basel; Mathias Nelle, 
MD, University Hospital, Berne; Bendicht Wagner, MD, 
University Hospital, Berne; Thomas Riedel, MD, Children’s 
Hospital, Chur; Grégoire Kaczala, MD, Cantonal Hospital, 
Fribourg; Riccardo E. Pfister, MD, University Hospital 
(HUG), Geneva; Jean-François Tolsa, MD, and Matthias 
Roth, MD, University Hospital (CHUV), Lausanne; Martin 
Stocker, MD, Children’s Hospital, Lucerne; Bernhard 
Laubscher, MD, Cantonal Hospital, Neuchatel; Andreas 
Malzacher, MD, Cantonal Hospital, St. Gallen; John P. 
Micallef, MD, Children’s Hospital, St. Gallen; Lukas Hegi, 
MD, Cantonal Hospital, Winterthur; Dirk Bassler, MD, 
and Romaine Arlettaz, MD, University Hospital (USZ), 
Zurich; Vera Bernet, MD, University Children’s Hospital, 
Zurich.
TIN Toscane on-line Network: Carlo Dani, MD, 
Careggi University Hospital, Florence, Italy; Patrizio 
Fiorini, MD, Anna Meyer Children’s University Hospital, 
Florence, Italy; Antonio Boldrini, MD, University Hospital 
of Pisa, Pisa, Italy; Barbara Tomasini, MD, University 
Hospital of Siena, Siena, Italy. 
UKNC (UK Neonatal Collaborative): Anita Mittal, 
MBChB, Bedford Hospital, Bedford, Bedfordshire; 
Jonathan  Kefas, MBChB, Lister Hospital, Stevenage, 
Hertfordshire; Anand Kamalanathan, MBChB, Arrowe 
Park Hospital, Wirral, Merseyside; Jayachandran, MBChB, 
Leighton Hospital, Crewe, Cheshire; Bill Yoxall, MBChB, 
Liverpool Women’s Hospital, Liverpool, Merseyside; 
Tim McBride, MBChB, Ormskirk District General 
Hospital, Ormskirk, Lancashire; Delyth Webb, MBChB, 
Warrington Hospital, Warrington, Cheshire; Ross Garr, 
MBChB, Whiston Hospital, Prescot, Merseyside; Ahmed 
Hassan, MBChB, Broomfield Hospital, Chelmsford, Essex; 
Priyadarshan Ambadkar, MBChB, James Paget Hospital, 
Gorleston, Norfolk; Mark Dyke, MBChB, Norfolk 
& Norwich University Hospital, Norwich, Norfolk; 
Katharine McDevitt, MBChB, Peterborough City Hospital, 
Peterborough, Cambridgeshire; Glynis Rewitzky, MBChB, 
Queen Elizabeth Hospital, King’s Lynn, Birmingham, West 
Midlands; Angela D’Amore, MBChB, Rosie Maternity 
Hospital, Addenbrookes, Cambridge, Cambridgeshire; 
Nagesh Panasa, MBChB, North Manchester General 
Hospital, Manchester, Greater Manchester; Paul Settle, 
MBChB, Royal Bolton Hospital, Bolton, Lancashire; 
Natasha Maddock, MBChB, Royal Oldham Hospital, 
Manchester, Greater Manchester; Ngozi Edi-Osagie, 
MBChB, St Mary’s Hospital, Manchester, Greater 
Manchester; Christos Zipitis, MBChB, The Robert Albert 
Edward Infirmary, Wrightington, Greater Manchester; 
Carrie Heal, MBChB, Stepping Hill Hospital, Stockport, 
Cheshire; Jacqeline Birch, MBChB, Tameside General 
Hospital, Ashton-under-Lyne, Lancashire; Abdul Hasib, 
MBChB, Darent Valley Hospital, Dartford, Kent; Aung 
Soe, MBChB, Medway Maritime Hospital, Gillingham, 
Kent; Niraj Kumar, MBChB, Queen Elizabeth The Queen 
Mother Hospital, Margate, Kent; Hamudi Kisat, MBChB, 
Tunbridge Wells Hospital, Tunbridge Wells, Kent; Vimal 
Vasu, MBChB, William Harvey Hospital, Ashford, Kent; 
Meera Lama, MBChB, Lancashire Women & Newborn 
Centre, Burnley, Lancashire; Richa Gupta, MBChB, Royal 
Preston Hospital, Preston, Lancashire; Chris Rawlingson, 
MBChB, Victoria Hospital,  Blackpool, Blackpool, 
Lancashire; Tim Wickham, MBChB, Barnet Hospital, 
Barnet, Hertfordshire; Marice Theron, MBChB, The 
Royal Free Hospital, Hampstead, London; Giles Kendall, 
MBChB, University College Hospital, Fitzrovia, London; 
Aashish Gupta, MBChB, Basildon Hospital, Basildon, 
Essex; Narendra Aladangady, MBChB, Homerton Hospital, 
Hackney, London; Imdad Ali, MBChB, Newham General 
Hospital,  Newham, London; Lesley Alsford, MBChB, 
North Middlesex University Hospital, Edmonton, London; 
Wilson Lopez, MBChB, Queen’s Hospital, Romford, Essex; 
Vadivelam Murthy, MBChB, The Royal London Hospital, 
Whitechapel, London; Caroline Sullivan, MBChB, Whipps 
Cross University Hospital, Whipps Cross, London; Mark 
Thomas, MBChB, Chelsea & Westminster Hospital, 
Chelsea, London; Tristan Bate, MBChB, Hillingdon 
Hospital, Hillingdon, London; Sunit Godambe, MBChB, 
Queen Charlotte’s Hospital, East Acton, London; Sunit 
Godambe, MBChB, St Mary’s Hospital, Westminister, 
London; Timothy Watts, MBChB, Guy’s & St Thomas’ 
Hospital, Lambeth, London; Jauro Kuna, MBChB, 
University Hospital Lewisham, Lewisham, London; 
John Chang, MBChB, Croydon University Hospital, 
Croydon, Surrey; Vinay Pai, MBChB, Kingston Hospital, 
Kingston, London; Charlotte Huddy, MBChB, St George’s 
Hospital, Wandsworth, London; Salim Yasin, MBChB, 
St. Helier Hospital, Merton, London; Richard Nicholl, 
MBChB, Northwick Park Hospital, Brent, London; 
Poornima Pandey, MBChB, Kettering General Hospital, 
Kettering, Northhamptonshire; Jonathan Cusack, MBChB, 
Leicester General Hospital, Leicester, Leicestershire; 
Venkatesh Kairamkonda, MBChB, Leicester Royal 
Infirmary, Leicester, Leicestershire; Dominic Muogbo, 
MBChB, Queen’s Hospital, Burton On Trent, Burton-
on-Trent, Staffordshire; Liza Harry, MBChB, Alexandra 
Hospital, Redditch, Worcestershire; Phil Simmons, 
MBChB, Birmingham Heartlands Hospital, Birmingham, 
West Midlands; Julie Nycyk, MBChB, City Hospital, 
Birmingham, West Midlands; Phil Simmons, MBChB, 
Good Hope Hospital, Birmingham, West Midlands; 
Andrew Gallagher, MBChB, Worcestershire Royal 
Hospital, Worcester, Worcestershire; Tilly Pillay, MBChB, 
New Cross Hospital, Wolverhampton, West Midlands; 
Sanjeev Deshpande, MBChB, Royal Shrewsbury Hospital, 
Shrewsbury, Shropshire; Mahadevan, MBChB, Russells 
Hall Hospital, Dudley, West Midlands; Alison Moore, 
MBChB, University Hospital of North Staffordshire, 
Hartshill, Staffordshire; Simon Clark, MBChB, The 
Jessop Wing, Sheffield, South Yorkshire; Mehdi Garbash, 
MBChB, Darlington Memorial Hospital, Darlington, 
County Durham; Mithilesh Lal, MBChB, James Cook 
University Hospital, Middlesborough, North Yorkshire; 
Majd Abu-Harb, MBChB, Sunderland Royal Hospital, 
Sunderland, Tyne and Wear; Mehdi Garbash, MBChB, 
University Hospital Of North Durham, Durham, Durham; 
Alex Allwood, MBChB, Derriford Hospital, Plymouth, 
Devon; Michael Selter, MBChB, North Devon District 
Hospital, Barnstaple, Devon; Paul Munyard, MBChB, 
Royal Cornwall Hospital, Truro, Cornwall; David Bartle, 
MBChB, Royal Devon & Exeter Hospital, Exeter, 
Devon; Siba Paul, MBChB, Torbay Hospital, Torquay, 
Devon; Graham Whincup, MBChB, Conquest Hospital, 
St.Leonards-on-sea, East Sussex; Abdus Mallik, MBChB, 
Frimley Park Hospital, Frimley, Surrey; Philip Amess, 
MBChB, Princess Royal Hospital,  Telford, Shropshire; 
Charles Godden, MBChB, Royal Surrey County Hospital, 
Guildford, Surrey; Philip Amess, MBChB, Royal Sussex 
County Hospital, Brighton, East Sussex; Peter Reynolds, 
MBChB, St Peter’s Hospital, Chertsey, Surrey; Indranil 
Misra, MBChB, Milton Keynes Foundation Trust Hospital, 
Milton Keynes, Buckinghamshire; Peter De Halpert, 
MBChB, Royal Berkshire Hospital, Reading, Berkshire; 
Sanjay Salgia, MBChB, Stoke Mandeville Hospital, 
Aylesbury, Buckinghamshire; Rekha Sanghavi, MBChB, 
Wexham Park Hospital, Slough, Berkshire; Ruth Wigfield, 
MBChB, Basingstoke & North Hampshire Hospital, 
Basingstoke, Hampshire; Abby Deketelaere, MBChB, 
Dorset County Hospital, Dorchester, Dorset; Minesh 
Khashu, MBChB, Poole Hospital NHS Foundation 
Trust, Poole, Dorset; Michael Hall, MBChB, Princess 
Anne Hospital, Southampton, Hampshire; Charlotte 
Groves, MBChB, Queen Alexandra Hospital, Portsmouth, 
Hampshire; Nick Brown, MBChB, Salisbury District 
Hospital, Salisbury, Wiltshire; Nick Brennan, MBChB, 
St Richard’s Hospital, Chichester, West Sussex; Katia 
Vamvakiti, MBChB, Worthing Hospital, Worthing, West 
Sussex; John McIntyre, MBChB, Royal Derby Hospital, 
Derby, Derbyshire; Simon Pirie, MBChB, Gloucestershire 
Royal Hospital, Gloucester, Glourcestershire; Stephen 
Jones, MBChB, Royal United Hospital, Avon, Somerset; 
Paul Mannix, MBChB, Southmead Hospital, Westbury-
on-Trym, Bristol; Pamela Cairns, MBChB, St Michael’s 
Hospital, Bristol, Bristol; Megan Eaton, MBChB, Yeovil 
District Hospital, Yeovil, Somerset; Karin Schwarz, 
MBChB, Calderdale Royal Hospital, Halifax, West 
Yorkshire; David Gibson, MBChB, Pinderfields General 
Hospital., Dewsbury, West Yorkshire; Lawrence Miall, 
MBChB, Leeds Neonatal Service, Leeds, Yorkshire; David 
Gibson, MBChB, Pinderfields General Hospital, Wakefield, 
West Yorkshire; Krishnamurthy, MBChB, Walsall Manor 
Hospital, Walsall, West Midlands.
Variables Characteristics
ID Unique ID assigned by site or coordinating center
Country Code for country (alphabetical list)
Center Code number 
Demographics
Gestational age Weeks and days
Birth weight kg
Birth year info Year 
Birth quarter info Quarter 
Age at NICU admission Hours:minutes
Sex Male/Female/Ambiguous/Unknown
Maternal age Years
Antenatal details  
Antenatal corticosteroid use Yes/No/Unknown
If YES, was it Complete/Incomplete/Unknown
Rupture of membranes duration <24 hours/24 hours to 1 week/>1 week /unknown or missing
Maternal high blood pressure All hypertensive disorders (pregnancy induced and otherwise)
Yes/No/Unknown or Missing
Maternal diabetes All glucose homeostasis disorders (pregnancy induced and otherwise)
Yes/No/Unknown or Missing
Birth details  
Mode of delivery Vaginal/Caesarean section/Unknown or missing
Presentation At birth or closest to the time of birth
Vertex/Breech/Other/Unknown or missing
Births this pregnancy If one of the fetus dies in-utero, pregnancy defined as twin/triplet as appropriate and not singleton or twin based on live births
Singleton/Twin/Triplet/Higher order
Birth order First/Second/Third/Forth/Unknown or missing
Place of birth Inborn applies to tertiary care hospital where NICU is located. Outborn includes those babies who needed to be transferred to NICU after birth for 
ongoing neonatal care from facility other than hospital in which they are cared for
Immediate postnatal care  
Need for intubation Within first 30 minutes of birth
Yes/No/Unknown or Missing
Need for CPAP Within first 30 minutes of birth
Yes/No/Unknown or Missing
Need for CPR during initial stabilization CPR includes chest compression and/or epinephrine 
Within first 30 minutes of birth
Yes/No/Unknown or Missing
Apgar at 1 minute 0 to 10, Unknown or Missing
Apgar at 5 minutes 0 to 10, Unknown or Missing
Admission status  
Re-admission Yes/No/Unknown or Missing
Admission head circumference (cm) Up to one decimal point
Admission length (cm) Up to one decimal point
Admission temperature (¢J) Up to one decimal point
Severity of illness score used Whatever score is used by network
Neonatal course  
Duration of supplemental O2 In days or hours (use midnight as cut-off)
Duration of CPAP In days or hours (use midnight as cut off)
Duration of mechanical ventilation In days or hours (use midnight as cut off)
Duration of TPN in days In days/hours (use midnight as cutoff)
Surfactant Yes/No/Unknown or Missing
Diagnoses/procedures  
PDA Clinical or echocardiographic diagnosis. We will collect information on method commonly used in separate survey
Yes/No/Unknown or Missing
Indomethacin or other NSAID for PDA treatment Yes/No/Unknown or Missing
Surgical ligation Yes/No/Unknown or Missing
RDS Clinical and/or radiological criteria
Yes/No/Unknown or Missing
Air leak Includes Pneumothorax, Pneumomediastinum
Yes/No/Unknown or Missing
Air Leak requiring drainage Needle paracentesis or chest tube will be included
Yes/No/Unknown or Missing
BPD at 28 days (need for supplemental oxygen) X-ray is not mandatory
Yes/No/Unknown or Missing
BPD at 36 weeks (need for supplemental oxygen) X-ray is not mandatory
Yes/No/Unknown or Missing
Postnatal steroid use for BPD Only systemic use (not inhaled steroid use)
Yes/No/Unknown or Missing
NEC (diagnosed using Bell’s criteria) Stage 2 or higher only
Yes/No/Unknown or Missing
Surgery for NEC (laparotomy/drainage)  Yes/No/Unknown or Missing
IVH (most severe grade) prior to discharge Classification could be SEH/GMH, IVH, VE, IPE
PVL or persistent parenchymal opacity Persistent intraparenchymal echolucency or cysts identified on US or MRI
Yes/No/Unknown or Missing
International ROP criteria In either eye, record the worst stage 
Treatment for ROP  Anti-VEGF or laser
Yes/No/Unknown or Missing
Early onset sepsis Infection within 72 hours (3 days) of birth—positive blood and/or CSF for pathogenic organism
Yes/No/Unknown or missing
Early onset sepsis If yes—organism
E. Coli/GBS/Other Gram negative bacteria/Other Gram positive bacteria/Fungal/Viral/Other/Unknown
Late onset sepsis Infection after 3 days (or 72 hours of age)—positive blood and/or CSF for pathogenic organism
LOS episode 1 Organism
If multiple organisms are grown in culture consider most virulent: Virulence should be counted as: Fungal–Gram negative (including E coli), Gram 
positive (including GBS), viral, mycoplasma, other in that sequence.
LOS episode 1 Postnatal age in days
LOS episode 2 Organism
If multiple organisms are grown in culture consider most virulent: Virulence should be counted as: Fungal–Gram negative (including E coli), Gram 
positive (including GBS), viral, mycoplasma, other in that sequence.
LOS episode 2 Postnatal age in days
LOS episode 3 Organism
If multiple organisms are grown in culture consider most virulent: Virulence should be counted as: Fungal–Gram negative (including E coli), Gram 
positive (including GBS), viral, mycoplasma, other in that sequence.
LOS episode 3 Postnatal age in days
LOS episode 4 Postnatal age in days
LOS episode 5 Postnatal age in days
Congenital anomalies Major congenital anomaly—defined as those life-threatening or likely to affect quality of way to a significant degree
Yes/No/Unknown or missing
If YES to above, please mention all congenital anomalies you have for a particular infant. 
Discharge Information  
Age at discharge/death Postnatal age in calendar days
Delivery room death Yes/No
Death Prior to discharge from NICU
Yes/No
Cause of death if available  
Discharge destination Home/Level 2 or HDU/SCBU/Pediatric ward/PICU/Out of area or country/Rehabilitation/palliative care/Unknown or missing/Other/Unknown
Breastfeeding/breast milk at discharge Yes/No/Unknown or missing
Oxygen at discharge Yes/No/Unknown or missing
Weight at discharge/death Kg
Oxygen at discharge Discharge information file
This includes deaths if baby died before discharge, enter information from last available recording
Yes/No/Unknown or missing
Weight at discharge Kg
Data fields added from 2017
MgSO4 for neuroprotection When given intrapartum
Yes/No/Unknown or missing
Presence of labor Prior to birth
Yes/No/Unknown or missing
Deferred or delayed cord clamping for >30 seconds Yes/No/Unknown or missing
Cord milking Yes/No/Unknown or missing
Age at surfactant administration Minutes
Inhaled nitric oxide At any time during NICU stay
Yes/No/Unknown or missing
Ever received mechanical ventilation At any time during NICU stay
Yes/No/Unknown or missing
Received INSURE Intubated, surfactant given and extubated within 30 minutes
Yes/No/Unknown or missing
LISA Received surfactant via less invasive method
Yes/No/Unknown or missing
Any postnatal steroid for BPD Anytime during NICU stay
Yes/No/Unknown or missing
Any respiratory support at 36 weeks Includes CPAP, high flow, mechanical ventilation, nasal cannula, 
Yes/No/Unknown or missing
Spontaneous intestinal perforation Yes/No/Unknown or missing
NEC treated with drain Yes/No/Unknown or missing
ROP plus disease Yes/No/Unknown or missing
Aggressive posterior ROP Yes/No/Unknown or missing
Age of first culture proven infection Days
Organism isolated in first infection Name of organism
Number of culture proven infections
Any episode of culture proven (blood or csf) for fungal infection Yes/No/Unknown or missing
Number of packed red blood cell transfusion
Death due to NEC Yes/No/Unknown or missing
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Funding for iNeo has been provided by a Canadian 
Institutes of Health Research Chair in Reproductive 
and Child Health Services and Policy Research (APR-
126340) held by PSS. The Australian and New Zealand 
Neonatal Network is predominantly funded by membership 
contributions from participating centers. The Canadian 
Neonatal Network is supported by a team grant from 
the Canadian Institutes of Health Research (CTP 
87518), the Ontario Ministry of Health, and individual 
participating centers. The Finnish Medical Birth Register is 
governmentally funded and kept by the National Institute 
for Health and Welfare (THL). The Israel Neonatal 
Network very low birth weight infant database is partially 
funded by the Israel Center for Disease Control and the 
Ministry of Health. The Neonatal Research Network 
of Japan is partly funded by a Health Labour Sciences 
Research Grant from the Ministry of Health, Labour and 
Welfare of Japan. SEN1500 is supported by funds from 
the Spanish Neonatal Society (SENeo). The Swedish 
Neonatal Quality Register is funded by the Swedish 
Government (Ministry of Health and Social Affairs) and the 
body of regional health care providers (County Councils). 
SwissNeoNet is partially funded by participating units in 
the form of membership fees. Tuscany Neonatal Network 
is funded by the Tuscany Region. The United Kingdom 
Neonatal Collaborative receives no core funding. MV 
acknowledges a research grant FIS17/0131 from the 
Instituto de Investigación Sanitaria Carlos III (Ministry of 
Science, Innovation and Universities; Kingdom of Spain) 
and RETICS funded by the PN 2018-2021 (Spain), ISCIII- 
Sub-Directorate General for Research Assessment and 
Promotion and the European Regional Development Fund 
(FEDER), reference RD16/0022.
Role of the Funders/Sponsors: The funding bodies 
played no role in the design and conduct of the study; 
collection, management, analysis, and interpretation of the 
data; preparation, review, or approval of the manuscript; 
and decision to submit the manuscript for publication.
Appendix 3 iNeo funding sources
Background
The overarching goal of iNeo collaboration is to generate 
new knowledge, develop quality improvement initiatives 
and monitor changes in outcomes and practices of neonates. 
In order to effectively use the dataset the following guiding 
principles for data sharing are developed which are based 
on the policy by Medical Research Council, UK.73 Results 
arising from the data collected and shared as a result of 
the iNeo collaboration are expected to meet the high 
standards of conducting database research including 
scientific quality and ethical requirements. A major impetus 
behind iNeo collaboration includes the provision that data 
arising from the iNeo collaboration will be available to the 
scientific community of participating networks with as few 
restrictions as possible so as to maximize the value of the 
data for research and for eventual patient and public benefit.
Currently, each network’s dataset are held by the 
individual networks. Within the framework of the iNeo 
collaboration, agreed minimal dataset for eligible infants 
from each network will be transferred to the iNeo 
Coordinating Centre after proper data transfer agreements 
are in place. These data will be accessed by iNeo 
Coordinating Centre research staff with the understanding 
that they are confidential to the iNeo collaboration only. 
Preliminary analyses will be conducted at iNeo coordinating 
center in Toronto.
In order to foster a true international collaboration, 
the data collected and housed at the iNeo Coordinating 
Centre will also be available to all iNeo member networks 
and iNeo-affiliated investigators after the principal 
analyses of this research proposal are completed. Specific 
collaborators/contributors from individual networks may 
take responsibility for certain analyses under the supervision 
of respective network director (who is a member of the 
iNeo Governing Board). In the initial phase, it will be 
preferred to send data requests to iNeo Coordinating center 
where analyses will be conducted and results will be sent to 
primary investigator(s). In the later phase of collaboration 
(after first year), it will be possible to either send dataset 
with requested variables to investigators or develop an 
“e-portal” where iNeo dataset could be assessed. 
An individual data request will first be discussed 
and approved by Scientific Advisory Board (made of 2 
individuals from each network). Once approved, SAB will 
direct the Governing Board to instruct iNeo coordinating 
center to conduct relevant analyses and in the later phase to 
release dataset to investigators. We are currently exploring 
the possibility of developing an “e-portal” whereby, under 
the supervision of their network director, researchers from 
all networks will be able to gain access to pre-packaged, 
anonymised and de-identified data subsets to address their 
research question. In the meantime, researchers interested 
in using the iNeo data will be asked to come in person to 
work collaboratively with statistical support available at the 
iNeo Coordinating Centre or to submit a request to the 
iNeo Coordinating Centre to have their analyses performed 
by members of the iNeo Coordinating Centre staff. 
In all scenarios/projects involving the analyses and/
or transfer of data out of the iNeo Coordinating Centre, 
approval of project proposals will be the responsibility of 
the iNeo Scientific Advisory Committee. The Scientific 
Advisory Committee will be formed of two members from 
each network and will be responsible for assessing additional 
projects proposed by member networks/individuals, 
approving requests for data transfer and analyses, evaluating 
the results of the primary analyses, advising member sites on 
knowledge translation, and taking lead roles in addressing 
Aims 3 and 4 of the research program. In the event that 
the iNeo collaboration cease to operate, the data collected 
will be managed according to the decision of the governing 
board (destruction or return the custody of dataset). At all 
times the iNeo Director, co-investigators and iNeo staff 
will ensure that data are held securely and a list of ongoing/
completed analyses are made available electronically via the 
iNeo website (www.ineonetwork.org).
Data sharing policy
Proposals for projects requiring data sharing and transfer 
will be considered by the iNeo Scientific Advisory 
Committee. In order to safeguard the scientific integrity 
and validity of the data, any new studies that request data 
to be shared to an individual network must receive approval 
from the Scientific Advisory Committee who will perform 
a peer review of the proposed project before granting such 
approval. This process will evaluate and confirm that the:
 Responsibilities and rights of all parties have been 
agreed at the outset;
 Proposed project has a clear scientific justification, 
anticipated output, and timeline;
 Appropriate regulatory permissions—ethical, legal and 
institutional—are in place before data can be shared;
 Funds required to support data extraction and transfer 
are in place; and
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 Proposals do not overlap with analysis that has been 
performed or is still being performed.
Privacy and confidentiality will be strictly maintained 
during any data collection and transfer according to 
local rules and regulations. No directly identifiable data 
will be collected or transmitted and in all reports only 
aggregate data will be presented. The iNeo Director will be 
responsible for coordinating applications for the  use of the 
data generated by the iNeo collaboration. This will ensure 
that the iNeo Director is aware of all planned analyses 
and publications in order to prevent duplication and to 
coordinate effective dissemination of information. 
The collection, collation and transfer of all data will 
be governed by ethical/regulatory approval from the 
local granting agencies of each member site and network. 
Approval from the Research Ethics Board at Mount Sinai 
Hospital, Toronto for the development, compilation, 
hosting and management of the iNeo dataset at the MiCare 
Research Centre will be obtained and maintained as up to 
date by the iNeo Director. 
Publication of approved studies
Researchers who use the iNeo data should send the 
penultimate draft of any publications to the iNeo Scientific 
Advisory Committee to ensure correct contextual 
interpretation of the dataset. A standard acknowledgement 
that needs to be included in any publication will be provided 
by the iNeo coordinator.  This will include but not limited 
to the following: “The iNeo Scientific Advisory Committee 
approved the use of the data included in this publication. 
Data were extracted from the original dataset for this study 
by members of the iNeo Coordinating Centre.”
The following outlines the policy on publications based 
on all analysis of the iNeo dataset and any other related 
projects:
(I) No publications should precede (i) publication of 
iNeo protocol, and (ii) publication of the results 
of the primary network-level analyses, for which 
the iNeo Governing Board and Scientific Advisory 
Committee will be listed as authors;
(II) All publications should have “iNeo Collaboration” 
as final author;
(III) The principal primary analyses comparing outcomes 
between the eight networks will include the names 
of all participating units from all networks. This 
list should be referred back to in each subsequent 
publication;
(IV) Publications subsequent to the publication of the 
primary analyses should be authored by individuals 
who meet the criteria for authorship as laid out by 
ICJME. These names should be followed by “iNeo 
Collaboration” as final author;
(V) All data requests will be handled on a first-come 
first-served basis. Individual investigators will have 
12 months to submit their work to journals for 
publication. After which they may lose right to the 
analyses and publish the results;
(VI) The names of the members of the iNeo Governing 
Board and Scientific Advisory Board should be 
listed in the Acknowledgements/at the end of each 
manuscript (subject to allowance by the journal);
(VII) Members of the iNeo Governing Board and 
Scientific Advisory Board could act as authors 
for individual projects depending upon their 
contribution to the project;
(VIII) For those publications arising from projects 
additional to the core research proposed here, a 
standard acknowledgement should be included 
in any publication: ‘The iNeo Scientific Advisory 
Committee approved the use of the data included 
in this publication. Data were extracted from the 
original dataset for this study by members of the 
iNeo Coordinating Centre.’;
(IX) Publications must conform to the rules of 
plagiarism and scientific accuracy at all times. This 
will be the responsibility of the authors of the 
publication;
(X) Prior to publication, all manuscripts should be 
submitted to the Scientific Advisory Board for their 
approval. The members of the Scientific Advisory 
Board will have 2 weeks to make a decision regarding 
approval and provide comments or suggestions. If no 
response is received, the project will be considered 
approved by the member of SAB;
(XI) Disagreement or disputes regarding authorship 
and publication should be brought to the attention 
of iNeo Governing Board. In such events, the 
decisions of the iNeo Governing Board will be 
binding to all parties involved.
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